Literature DB >> 17823952

Modifications in low-density lipoprotein receptor expression affects Cyclosporin A cellular uptake and cytotoxicity.

Carlos Leon1, Jessica Jia, Guosong Qiu, John S Hill, Kishor M Wasan.   

Abstract

The purpose of this study was to test the effect of modulating the expression of the human low-density lipoprotein receptor (LDLr) in human embryonic kidney (293T) cells on Cyclosporin A (CsA) cellular uptake and CsA-mediated cytotoxicity. LDLr expression was modulated using RNA interference (RNAi) and an LDLr overexpression plasmid. One of the small-interfering RNA (siRNA) constructs, LDLr-792, showed a 60% decrease in LDLr protein expression. The downregulation effect was specific as transfection with an annexin V (AxV) siRNA construct did not decrease LDLr expression levels. AxV and ABCA1 expression levels were not affected in the cells transfected with LDLr-792 (LDLr(LOW) cells) compared to the controls. At a functional level, fluorescent low-density lipoprotein (LDL) (DiI-LDL) internalization in the LDLr(LOW) cells was decreased (30%) compared to control cells. We tested the dose-dependent cytotoxicity induced by CsA using a respiration assay. We found a decrease in CsA-mediated cytotoxicity in the range of CsA doses studied (1-10 microg/mL) in the LDLr(LOW) cells compared to the pSHAG-transfected cells, reaching a statistical significance at 10 microg/mL CsA. At higher CsA doses we found a significant decrease in LDLr expression. When the control and LDLr(LOW) cells were treated with another cytotoxic drug, gentamycin, there was no difference in the cell viability, suggesting that this effect is specific for CsA. We confirmed the association of LDLr expression levels with CsA uptake by overexpressing the LDLr. The LDLr overexpressing cells showed an enhanced uptake of radiolabelled CsA. Taken together these results suggest that CsA internalization and cytotoxicity are affected by the LDL receptor expression levels. 2007 Wiley-Liss, Inc

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 17823952     DOI: 10.1002/jps.21141

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  2 in total

1.  Immediate therapeutic efficacy of low-density lipoprotein apheresis for drug-resistant nephrotic syndrome: evidence from the short-term results from the POLARIS Study.

Authors:  Eri Muso; Masatoshi Mune; Tsutomu Hirano; Motoshi Hattori; Kenjiro Kimura; Tsuyoshi Watanabe; Hitoshi Yokoyama; Hiroshi Sato; Shunya Uchida; Takashi Wada; Tetsuo Shoji; Yukio Yuzawa; Tsukasa Takemura; Satoshi Sugiyama; Yoshiki Nishizawa; Satoru Ogahara; Noriaki Yorioka; Soichi Sakai; Yosuke Ogura; Susumu Yukawa; Yasuhiko Iino; Enyu Imai; Seiichi Matsuo; Takao Saito
Journal:  Clin Exp Nephrol       Date:  2014-06-17       Impact factor: 2.801

2.  A Prospective Observational Survey on the Long-Term Effect of LDL Apheresis on Drug-Resistant Nephrotic Syndrome.

Authors:  Eri Muso; Masatoshi Mune; Tsutomu Hirano; Motoshi Hattori; Kenjiro Kimura; Tsuyoshi Watanabe; Hitoshi Yokoyama; Hiroshi Sato; Shunya Uchida; Takashi Wada; Tetsuo Shoji; Tsukasa Takemura; Yukio Yuzawa; Satoru Ogahara; Satoshi Sugiyama; Yasuhiko Iino; Soichi Sakai; Yousuke Ogura; Susumu Yukawa; Yoshiki Nishizawa; Noriaki Yorioka; Enyu Imai; Seiichi Matsuo; Takao Saito
Journal:  Nephron Extra       Date:  2015-08-29
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.